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DURING the last few decades it has been recognized that
cell death is not the consequence of accidental injury, but
is the expression of a cell suicide programme. Kerr et aL
(1972) introduced the term apoptosis. This form of cell
death is under the influence ofhormones, growth factors
and cytokines, which depending upon the receptors
present on the target cells, may activate a genetically
controlled cell elimination process. During apoptosis the
cell membrane remains intact and the cell breaks into
apoptotic bodies, which are phagocytosed. Apoptosis, in
contrast to necrosis, is not harmful to the host and does
not induce any inflammatory reaction. The principal
event that leads to inflammatory disease is cell damage,
induced by chemical/physical injury, anoxia or starva-
tion. Cell damage means leakage of cell contents into the
adjacent tissues, resulting in the capillary transmigration
ofgranulocytes to the injured tissue. The accumulation of
neutrophils and release of enzymes and oxygen radicals
enhances the inflammatory reaction. Until now there has
been little research into the factors controlling the accu-
mulation and the tissue load of granulocytes and their
histotoxic products in inflammatory processes.
Neutrophil apoptosis may represent an important event
in the control of intlamtnation. R has been assumed that
granulocytes disintegrate to apoptotic bodies before their
fragments are removed by local macrophages. Removal
of neutrophils from the inflammatory site without re-
lease of granule contents is ofparamount importance for
cessation of inflammation. In conclusion, apoptotic cell
death plays an important role in inflammatory processes
and in the resolution ofinflammatory reactions. The facts
known at present should stimulate further research into
the role of neutrophtl, eosinophil and macrophage
apoptosis in inflammatory diseases.
Key words: Apoptosis, Cytokines, Growth factors, Hormones,
Inflammation, Integrins.
Apoptosis and inflammation
C. Haanen and I. Vermesc*
Department of Clinical Chemistry, Medical
Spectrum Twente, P.O. Box 50.000, NL-7500
KA Enschede, The Netherlands
ca Corresponding Author
Introduction
During the last few decades it has been recognized
that cell death is generally not the consequence of
ageing or accidental injury, but that cells die as the
expression of a genetically programmed active cell
suicide. This physiological form of cell death, which
is profoundly influenced by the extracellular
microenvironment, is of fundamental significance in
embryogenesis, morphogenesis, and in the pro-
cesses that govern tissue shape and cell renewal.
Active elimination of cells was observed originally in
1951 by GlOcksmann and in 1966 by Saunders as an
essential feature in the development of vertebrates
and invertebrates, respectively. They recognized pro-
grammed cell death as a mechanism by which un-
wanted or useless cells are eliminated. In the past ten
years it has become increasingly apparent that pro-
grammed cell death occurs not only during embry-
onic development, but appears to be a widespread
phenomenon, and a dynamic balance between cell
proliferation and cell elimination.,4 Programmed cell
death is responsible for the deletion of useless,
unwanted or crippled cells, remodelling of organs,
canalization of ducts, fashioning of the body, forma-
tion of digits, and fusion of palatal shelves.
Necrosis has been the traditional term for acciden-
tal cell death. Necrosis occurs in response to harmful
insults such as physical damage, hypoxia,
hyperthermia, starvation, complement attack, and
chemical injury. The earliest morphological changes
that occur during necrosis, are swelling of the cyto-
plasm and organelles. These changes are the expres-
sion of the loss of selective permeability of the
cytoplasmic membrane. This demolition results in
dissolution of the organelles, leaking of the cellular
contents into the extracellular space, and finally in
the disappearance of the cytoplasmic membrane.
Necrosis affects tissue areas or groups of contiguous
cells and elicits an inflammatory reaction in the
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adjacent viable tissues in response to the released
cell debris.
Apoptosis shows, morphologically, a distinct pat-
tern of cell resolution. The earliest changes include
the loss of cell junctions and specialized membrane
structures such as microvilli. The cytoplasm shrinks
and the nucleus coalesces into condensed masses,
which later break up into fragments. The
mitochondria initially remain intact. The
endoplasmic reticulum transforms into vesicles that
fuse with the cytoplasmic membrane. These pro-
cesses result in contraction of the cytoplasmic vol-
ume, associated with the loss of intracellular fluid
and ions. The cell adopts a convoluted outline and
subsequently breaks into several membrane-en-
closed apoptotic bodies containing well-preserved
organelles and nuclear fragments. The apoptotic
bodies are phagocytosed and digested by nearby
resident cells. The engulfing cells belong mostly to
the mononuclear-phagocyte system, but epithelial or
endothelial cells, and even tumour cells, may also be
involved. It has been recognized that apoptotic bod-
ies themselves provide a stimulus for phagocytosis
by changes on their cytoplasmic membrane. Once
ingested the apoptotic bodies undergo rapid degra-
dation. Apoptosis does not induce any inflammatory
reaction. A characteristic biochemical feature of the
process is double-strand cleavage of nuclear DNA at
the linker regions between nucleosomes, leading to
the production of oligonucleosomal fragments of
+ 200 kDa or multiples of it. Apoptosis is not harmful
to the host and is in fact necessary for a normal
existence. Distinctive morphological and biochemi-
cal characteristics have been reviewed by Wyllie et
al.3 and Trump et al.5
In 1972 Kerr et al. described the ultrastructural and
morphological differences that can be observed be-
tween necrosis and programmed cell death6. They
introduced the term apoptosis as opposite to that of
necrosis. Apoptosis is derived from the Greek term
0trtort’mmg that indicates the fall of leaves from trees
or the shedding of petals from flowers.
At present, the term apoptosis is often used syn-
onymously with programmed cell death. The
melding of the two concepts may lead to confusion.
Programmed cell death is the definition of a ’con-
certed programme’ of cell elimination during meta-
morphosis, embryogenesis and morphogenesis.
Apoptosis indicates the phenomenon of ’physiologi-
cal cell death,’ which does not include any program-
ming.
Apoptosis takes place during embryogenesis, dur-
ing the development of the nervous system and the
immune system, in the course of normal tissue turn
over, and after withdrawal of trophic hormones or
cytokines from target tissues. Apoptosis is implicated
in the homeostatic cell balance in normal adult tis-
sues such as intestinal crypts, the skin, the
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haematopoietic system. Neutrophils undergo
apoptosis during resolution of the inflammatory re-
action. Apoptosis of lymphocytes is an essential
mechanism in the regulation of the immune system.
It occurs during evolution of hormone dependent
organs (prostate, endometrium, mammary tissue).
Cell injury due to a variety of agents (viral infection,
physical injury, chemical insults) may also lead to
apoptosis. In general, any event that can produce
necrosis by cell destruction (toxins, radiation) can
induce apoptosis if the cell initially survives. Finally
apoptosis has been demonstrated in premalignant
and malignant tissues. Comprehensive reviews have
recently been given by Ellis et al., Alison and.
Saraf, Cohen, Schwartzman and Cidlowski,
1
Gewitz,
11 and Vermes and Haanen. 12
The most prominent morphological features and
biochemical differences between apoptosis and
necrosis are summarized in Table 1. This review
covers present knowledge about mediators and
modulators of apoptosis, and the biochemical
mechanisms and its genetic control. Special emphasis
is given to the influence of hormones, cytokines and
growth factors in the occurrence of apoptosis and to
the role of apoptosis in inflammatory disease.
Mediators/Modulators of Apoptosis
Apoptosis is induced by stimuli that trigger
intracellular responses that result in a characteristic
type of cell death. This concept implies the existence
of specific stimuli and the presence of target cells. An
important characteristic of apoptosis is that it is in-
duced by withdrawal of cell specific stimuli and can
be inhibited by the action of cell specific hormones,
growth factors and mitogens. We may speculate
about the advantages of celt survival, depending
upon signals produced by other cells. One possibility
is that it could provide a mechanism for eliminating
cells that end up in an abnormal location. For exam-
ple, when a tissue is lacerated, cells may become
displaced or transported by the circulation into
places where they could cause trouble if they sur-
vived and proliferated. The same mechanism may
prevent haematopoietic stem cells from proliferating
outside the bone marrow, or cancer cells from estab-
lishing metastases. Another advantage of cell survival
being independent of the presence of specific
growth factors, is that control of the total number of
distinct cell types, because they have to compete for
limiting amounts of growth factors, establishes a
continuous selection for the most competitive and
vital cells.
Hormones: In mammals apoptosis is prominent in
certain tissues undergoing atrophy as a result of
withdrawal of hormones. It is observed during tissue
involution, for example in the uterus after deliveryApoptosis and inflammation
Table 1. Morphological and biochemical differences between apoptosis and necrosis
Features Apoptosis Necrosis
Stimuli
Origin
Occult phase
Adhesion property
First manifestation
Nuclear changes
Nuclear chromatin
Nucleolar changes
Membrane integrity
Surface morphology
Surface changes
Cytoskeletal changes
Mitochondria
ER/Golgi apparatus
Organelles
Protein synthesis
Cytoplasmatic changes
Nuclear changes
Cells affected
Cell elimination
Scar formation
Physiological
Lack of growth factor
Hormonal influence
Mild toxic stimulus
Minutes to hours
Immediately lost
Cell shrinking
Condensation, karyorrhexis
Margination, segmentation
Intact, later degraded
Persists for some time
Smoothing, blebbing
Expression vitronectin
thrombospondin
Surface protrusions
Cytoplasmic budding
Formation of apoptotic bodies
Initially unaffected
Initially unaffected
Structurally intact
Process can be blocked by
actinomycin D,
cycloheximide
Ca
2/ T, endonuclease T
transglutaminase 1"
p53 , bcl-2,1,, c-myc T
Internucleosome cleavage
DNA laddering
Individual cells
Scattered cells
Engulfment by macrophages
and endothelial cells
Absent
Pathological
Anoxia, Starvation
Physical insult
Chemical injury
None
Initially intact
Cell ,swelling
Karyolysis
Nuclear folding
Granulated
Early failure
Lysis
None
None
Fragmentation
Leakage of cellular contents
Swelling, Ca
2/ uptake
Dilated
Swollen, leaky
Not affected by antibiotics
Rupture lysosomes
Release of content
Diffuse degradation
DNA smear
Groups of contiguous cells,
tissue areas
Exudative inflammation in
adjacent tissues
Present
and in the breast gland after weaning.
Hypophysectomy induces apoptosis in the adrenal
cortex and in the thyroid gland. Apoptosis occurs in
endometrial cells deprived of steroid hormones13,14
and in the prostatic glandular acini after
orchidectomy. 15 While some hormones prevent
apoptotic death of susceptible cells, others trigger
apoptosis; for example, corticosteroids in thymocytes
and lymphocytes (see Table 2).,16 The mechanism of
lymphocyte killing by glucocorticoids is unclear.
Transcriptional regulation is implicated since an in-
tact transcriptional transactivation domain of the
glucocorticoid receptor gene is required.
17 In all these
examples the signals that either trigger or prevent
apoptosis also control other aspects of growth and
development of susceptible cells. In other words
both cell replication and cell death are regulated in
concert to produce growth and cell regression, and
to balance the size of organs.
Growthfactors: It has been suggested that all animal
cells are dependent on the presence of at least one
survival factor. 18 These survival factors include
growth factors. The nerve growth factor (NGF) was
the first growth factor to be identified and character-
ized. Neurons die if they receive inadequate
neurotrophic support; conversely neuronal death is
prevented when exogenous NGF is provided.
19,2
There is evidence that the targets of neurons may not
be the only source of NGF and that other peptides
may act as a survival signal for neurons and glial
cells. Such peptides include platelet derived growth
factor (PDGF), insulin-like growth factor (IGF),
fibroblast growth factor (FGF) and ciliary
neurotrophic factor (CNTF). ’1-25 Cells that are in cycle
are much more dependent upon the presence of
growth factors, than are non-cycling cells. Fibroblasts
engineered to express c-myc and which therefore
constitutively remain in cycle, undergo apoptosis
when deprived of a restricted group of cytokines,
principally IGF an PDGF. 26 The death of
haematopoietic cells, such as normoblasts,
neutrophils and megakaryocytes, has the morpho-
logical and biochemical characteristics of apoptosis.
The suppression of apoptotic cell death of
haematopoietic (precursor) cells requires the con-
tinuous presence of haematopoietic growth factors
such as erythropoietin (EPO) and colony stimulating
factors (CSFs).27 Next to CSFs, IGF also prevents the
occurrence of apoptosis in IL-3 dependent
haematopoietic cells. 28 Apoptosis of erythroid pro-
genitor cells is suppressed by erythropoietin
(EPO).29, Williams et al. 27 observed that occurrence
of apoptotic death of myelo-monocytic progenitor
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Table 2. Enhancement or suppression of apoptosis by tissue specific hormones, growth factors and cytokines
Cells/tissues Apoptosis
Enhance Suppress
Hormones
Adrenal cortex Adrenocorticotropic hormone
Prostrate Testosterone
Endometrium Oestrogen hormone
Progesterone
Thymocytes Corticoids
Growth factors
Neurons NGF, PDGF, IGF, FGF, CNTF
Primordial germ cells SCF
Endothelial cells FGF
Haemopoietic cells IGF
Myeloid progenitor cells CSFs, G-CSF, GM-CFS
Neutrophils NGF
Mast cells IGF-1
7-M12 leukaemia cell line TGF-II
Tumour cells Gfs (autocine production)
Cytokines
Neurons LIF
Haemopoietic(precursor)cells IL-3
Activated precursor cells TNF(
Neutrophils IL-3
TNFo
Eosinophils IL-5
Mast cells IL-3
Monocytes/macrophages IL-11, TNF(z
Stimulated monocytes/ IL-4
macrophages IFN3,
Thymocytes TNF
T-lymphocytes IL-2, IL-4
CD4+/CD8+ T-lymphocytes IL-2
Megakaryoblasts IL-11
B-chron. lymph, leukaemia IL-4
blc2 + chronic lymphatic leukaemia IL-4
7-M12 leukaemia cell line IL-3, IL-6
Tumour cells Cytokines (autocrine production)
Abbreviations: CNTF, ciliary neutrophic factor; CSF, colony stimulating factor; G-CSF, granulocyte CSF; GM-CSF, granulocyte/monocyte
CSF; FGF, fibroblast growth factor; IFN, interferon; IL, interleukin; IGF, insulin like growth factor; LIF, leukaemia inhibiting factor; NGF, nerve
growth factor; PDGF, platelet derived growth factor; TGF, transforming growth factor; TNF, tumour necrosis factor; SCF, stem cell factor.
cells was suppressed when either granulocyte colony
stimulating factor (G-CSF) or granulocyte-
macrophage colony stimulating factor (GM-CSF) was
added to the culture medium. Just like the
granulocyte-macrophage precursors, which are lost
during culturing unless exposed to GM-CSF or G-
CSF, the survival of neutrophils is dependent upon
the continuous presence of these factors.1.32Recently
it has been described that nerve growth factor (NGF)
has an inhibitory effect on the occurrence of apop-
tosis in murine peritoneal neutrophils.3 Endothelial
cells in culture undergo apoptosis when deprived of
FGF.4 A mechanism by which various tumour cells
evade apoptosis is by the autocrine production of
various survival factors, such as IGF or cytokines.
In conclusion, as indicated in Table 2, various
types of growth factors, such as CSFs, FGF, PDGF,
NGF and IGF inhibit apoptosis of susceptible cells.
Cytokines: Not only growth factors control cell pro-
liferation and maturation, for cytokines also modu-
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late the viability of the cells. Apoptosis of sympa-
thetic neurons is inhibited by NGF, but is enhanced
by leukaemia inhibitory factor (LIF).5 The same
mechanism applies for cycling haematopoietic pro-
genitor cells, which undergo apoptosis under the
influence of tumour necrosis factor-ot(TNF(,),6 or
when certain cytokines (e.g. IL-3) are removed.7,8
Many authors have shown that apoptotic death of
haemopoietic progenitor cells is prevented by addi-
tion of interleukin-3 (IL-3).9-4 The cytokine IL-3
regulates the development and differentiation of
neutrophils in concert with CSFs.31-42 Erythropoietin
(EPO) retards DNA breakdown and prevents
apoptosis in erythroid progenitor cells.44 The
haematopoietic cytokines EPO, IL-3 and stem cell
factor (SCF) are necessary during the mid-gestation
haematopoietic development in the foetal mouse
liver to protect these cells from apoptosis in liver
during ontogeny.45 Mature neutrophils undergo
apoptosis on ageing,4<47 a process that is enhanced
by tumour necrosis factor-o(TNFo0. TNF also en-Apoptosis and inflammation
hances cAMP induced apoptosis in mouse
thymocytes48’49 and in the human histiocytic
lymphoma cell line U937.5 TNF secreted by
lymphocytes and macrophages, triggers apoptosis in
many cell types. Apoptosis induced in the murine
leukaemia cell line 7-M12 by transforming growth
factor (TGF-II) or cytotoxic agents, can be counter-
acted by IL-3 and IL-6. 51
Mature T lymphocytes undergo apoptosis when
deprived of IL-2, 52,53 whereas IL-2 primes CD4 + and
CD8+ mouse T lymphocytes to undergo apoptosis
when, subsequently, they are exposed to antigen
which triggers the TCR. 54’55 IL-2 and IL-4 selectively
rescue T cell subsets from glucocorticoid-induced
apoptosis. 56 IL-4 inhibits apoptotic cell death in B-cell
chronic lymphocytic leukaemia cells in vitro. 57
The rate of apoptosis of human eosinophils, which
is slower than that reported for neutrophils, is de-
layed in vitro by the eosinophil differentiation factor
IL-5, which appears to have no effect on neutrophil
apoptosis. 24,58,59 Therefore, despite the close
haematopoietic origin of eosinophils and
neutrophils, apoptosis and longevity, like their
growth and differentiation, are controlled by differ-
ent specific growth factors and cytokines.
During apoptosis of monocytes/macrophages IL-1
is released, which binds with high affinity to specific
receptors on target cells.6 TNFot and IL-113 prevent
apoptotic death in human monocytes/
macrophages.1 Apoptosis of stimulated monocytes/
macrophages is inhibited by IFNq, (from TH-1 cells
and enhanced by IL-4 (from TH-2 cells).62 Murine
mast cells undergo apoptosis on removal of IL-3.63
Human megakaryoblastic cell lines produce IL-11,
which acts as an autocrine growth factor in these
cells.4
In conclusion, as summarized in Table 2, cytokines
released by lymphocytes, monocytes or
macrophages, which bind to cell receptors, modulate
the viability and occurrence of apoptotic death in
susceptible cells.
Killer cells/cytotoxic lymphocytes: During the matura-
tion of T-lymphocytes in the thymus, a rearrange-
ment takes place in the T-cell receptor genes, which
resultg in the production ofT cells with a tremendous
variety of T-cell receptors (TCRs). This random pro-
cess results in many T cells that bear TCRs and can
react against components of their own tissues. Self-
reactive T cells are potentially dangerous and must
be eliminated before they enter the circulation. In the
thymus the T cells that react with self-antigens un-
dergo apoptosis, a negative selection procedure. T
cells must not only learn to avoid attacking self-
antigens, they must also learn to detect their targets
only when encountered as a peptide presented as
localized in the groove of the major
histocompatibility complex (MHC) on the surface of
an antigen-presenting cell. This is a positive selection
procedure, known as MHC restriction. Consequently,
immature T cells that bind to self-antigens or to
antigens not presented in association with the MHC
complex are eliminated by apoptosis.5-7 T cells
which survive the selection procedure go on to reach
maturity and leave the thymus.
The MHC molecules consist of two types: (1) Class
MHC displays peptides from proteins made inside
a cell (e.g. virus infected cells, cancer cells); and (2)
Class II MHC displays peptides from proteins that
have entered the cell from outside (e.g. foreign,
abnormal, altered proteins, bacterial toxins).
T-lymphocytes occur in two varieties, depending
upon the structure of a co-receptor next to TCR:
(1) T cells with co-receptor CD8+ recognize antigens
only when displayed by Class MHC and be-
come cytotoxic lymphocytes (CTL) or natural
killer (NK) cells. CTLs and NK cells recognize
foreign antigens displayed by aberrrant, malig-
nant or virus-infected cells, which they then
destroy by inducing apoptosis.
(2) T cells with co-receptor CD4+ recognize antigens
only when presented by Class II MHC and
become T helper cells (TH cells). TH cells
produce interleukins (ILs); factors that spur other
T or B cells into action, such as gamma
interferon (IFNT) <---TH-1 cells and IL-4 <--TH-2
cells.8
A CTL with a TCR that fits onto an MHC/antigen
complex presented by a macrophage, brings IL-2
receptors to expression. In case of TCR activation
under the influence of IL-2, the IL-2 receptors en-
hance the TCR/CD-3 signal to the nucleus to start CTL
cell reduplication. Otherwise, when deprived of IL-
2, the CTLs undergo apoptosis. After antigen clear-
ance, IL-2 production ceases because TH cells are no
longer stimulated and consequently the antigen re-
sponsive T cells undergo apoptosis. This mechanism
has the physiological role of terminating the immune
response and reducing the increased cell numbers to
original proportions.
Unlike T cells, B cells secrete their receptors, which
then circulate in the blood as antibodies. These
antibodies lock onto antigens and help to destroy
them. B cells express the same variety in antibody
production as do the T cells in their TCRs. If antibod-
ies present on B cells engage with an antigen, these
cells are stimulated to proliferate and to secrete large
amounts of the same kind of antibodies. One of the
remarkable qualities of immunoglobulin production
is that the affinity of the antibodies to antigen im-
proves during the period of immune reaction. This is
due to the fact that the B cells, which carry the most
avidly binding antibodies, are stimulated to prolifer-
ate at the expense of those bearing the poorer
antibodies, which are deleted by apoptosis.9, Ger-
minal centre B cells, which do not receive antigen
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stimulation of their surface immunoglobulin, un-
dergo apoptosis.
71
Comprehensive reviews about apoptosis in
immunogenesis have been given by Golstein et aL,72
Von Boehmer,73 Cohen and Duke,74 Fesus75 and
Kabelitz et aL6 Summarizing, the immune system is
’taught’ during its development and in further life, to
distinguish between self and non-self and to improve
the quality of the immune response, where apoptosis
is their ’teacher’.
Cell receptors.. There are a number of similarities
between apoptotic cell death and CTL or NK cell
mediated cytolysis, which suggest that these cells
activate an endogenous cell death programme in the
target cell. From available data it is supposed that
CTL-mediated cytolysis involves two mechanisms:
(1) engagement of the CTL-TCR with an antigen/
receptor on the surface of the target cell results in
activation of the cell death programme in the target
cell; and (2) the same engagement stimulates the
release from the CTL of lytic granules that contain
perforins and fragmentins, which damage the cellular
membrane of the target cell. The relative contribu-
tions of membrane and apoptotic damage in CTL
mediated cytolysis are unknown. NK cells, together
with TNF, secreted by TH cells/macrophages, are
able to trigger apoptosis in many cell types. When T
cells are deprived of cytokines, then mature T cells
undergo apoptosis. T cells also undergo apoptosis,
when the triggering of the auxiliary surface molecule
CD4 of T cells occurs, uncoupled from TCR trigger-
ing.77 For instance, by this mechanism, CD4 trigger-
ing ofT lymphocytes by the HIV-1 viral envelope gp-
120 may induce apoptosis of T lymphocytes that are
not even infected, thus explaining the T-cell deple-
tion in AIDS patients.TM
Genes: Several genes have been associated with
apoptosis, either because they are expressed or not
during apoptosis and because their expression/sup-
pression affects the process of apoptosis. A very
characteristic biochemical event in apoptosis is the
double strand cleavage of nuclear DNA at the linker
regions between the nucleosomes. This results in a
number of 180-200 base pair fragments and multi-
ples of it, which become visible as a ladder pattern
on agarose gel electrophoresis of the DNA extracted
from apoptotic cells. In contrast, in necrosis the DNA
breakdown occurs randomly, which results in DNA
fragments that present as a smear in electrophoresis
of DNA extracted from necrotic cells. DNA damage
induced by radiation or cytotoxic drugs can lead to
apoptosis. It is even likely that most
chemotherapeutic drugs induce tumour cell
apoptosis rather than inhibit tumour cell prolifera-
tion. 37 It has been shown that there is a lag period of
several hours between the triggering and the occur-
rence of apoptosis, suggesting the probable need for
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RNA and protein synthesis. Administration of RNA
and protein synthesis-inhibitors results in suppres-
sion or delay or apoptosis. Knowledge about the
genes that regulate the intracellular biochemical
processes is still fragmentary. A number of genes and
gene products* have been implicated in the control
of apoptosis. In mammalian systems these include:
Fas/APO=I, bcl-2, (c-myc c-myb, c-fos, c-jun), p53,
ced-3/ICE, TRPM-2/SGP. In the following sections
details are given of those genes and gene products
where a role in the apoptotic process has been
demonstrated.
Fas gene/APO-1 molecule. Fas is a gene, whose
product (Fas) is a membrane-spanning protein, ho-
mologous to tumour necrosis factor (TNF) receptor
and nerve growth factor (NGF) receptor.
79,8 TNF
induces surface receptor apoptosis in ta.rget cells via
this cell. The Fas product is identical to the cell
surface molecule APO-1.81 Fas/APO-1 cross-linking
by antibody induces apoptosis, which indicates that
Fas product, APO-1, mediates an apoptotic signal
into the cells. Apo-1 has been shown to be expressed
in human B lymphocytic leukaemia cells. Bcl-2 ex-
pression is down-regulated and APO-1 expression
upregulated by exposition to IL-2, which prepares
the cells for anti-Fas/Apo-1 mediated apoptosis.
2
The Fas/APO-1 system has also been shown to be
the target molecule for cytotoxic T cells. Mice bear-
ing the lpr mutation are defective in Fas, and the
thymoma, that they develop is not due to T cell
proliferation but to cell accumulation, because the
thymocytes die less readily than their normal coun-
terparts.
84
Bcl-2 gene. The bcl-2 oncogene was first identified
as a gene over-expressed in human follicular B-cell
lymphomas, following reciprocal chromosomal
translocation t(14; 18)(q32; q21). In this aberration a
translocation of the proto-oncogene bcl-2 (B Cell
Lymphoma-2_) on chromosome 18 to the IgH locus
on the JH segment of the immune gene on chromo-
some 14 has occurred. When over-expressed bcl-2
inhibits apoptosis in a variety of cells including
cytokine/growth factor-deprived haematopoietic
cells and neurons.5-7 Bcl-2 does not stimulate cell
proliferation, but promotes survival of cells in a non-
cycling state. Bcl-2 co-operates with disregulated c-
myc expression to promote haematopoietic tumour
development in transgenic mice. Since bcl-2 inhibits
induction of apoptosis by c-myc, the basis of this co-
operation is presumably the preservation from
apoptosis by bcl-2 of c-myc-expressing target cells,
which then can proliferate. Bcl-2 renders cells less
sensitive to radiation and to cytotoxic drugs; only
CTL killing is not inhibited.6 The mechanism by
In the text, genes are given in italic characters and gene
products in roman characters.apoptosis and inflammation
which bcl-2 blocks apoptosis is unknown, but it may
be related to the fact that the gene product resides at
the inner side of the mitochondria, which remain
intact during a large part of the apoptotic process. An
attractive hypothesis is that bcl-2 protects cells by
inhibiting lipid peroxidation, even in the presence of
reactive oxygen intermediates.
88 Recently, a number
of bcl-2-related genes have been identified, includ-
ing bax, bcl-x, mcll, E1B (in adenovirus), LMW5-HL
(in African swine fever virus), BHRF1 (in
Epstein-Barr virus).
C-myc gene. Growth factors induce expression of
the oncogene c-myc, which indicates that expression
of c-myc is associated with cell proliferation.89 Other-
wise, deprivation of growth factors causes down-
regulation of c-myc and is accompanied by growth
arrest or induces in cells with a high expression of c-
myc apoptosis.9 The c-myc protein has apparently a
dual role: (1) promoting proliferation in the presence
of a relative abundance of appropriate growth fac-
tors; and (2) inducing apoptosis when c-myc is ex-
pressed in cells during growth arrest.91 Vaux et al.5
showed that expression of the bcl-2 gene in pre-B
cells of transgenic mice with a high expression of c-
myc promotes survival of these cells, which means
that bcl-2 co-operates with c-myc to immortalize pre-
B cells. The role of growth factor in relation to c-myc
expression can be summarized as follows
Growth factor (GF)
--+ c-myc expression q"
GF deprivation
-+ c-myc expression $
GF deprivation
+ c-myc expression "I" "1"
--+ cell proliferation
--+ cell in GO
--+ apoptosis
p53 protein. Many studies concerning the p53
protein have shown that this protein has a tumour
suppressor activity, which is illustrated by the fact
that p53 is the most commonly disrupted gene in
human malignancies.92 It has been demonstrated that
the p53 protein forms a complex with the cell cycle
regulating protein cdc2-kinase after which the cell
becomes arrested in the G1-phase or may switch to
a differentiation mode.% In cells where DNA damage
has occurred, e.g. after UV or gamma irradiation or
after chemotherapy, the p53 protein accumulates and
cell proliferation is arrested.94-9a Possibly this mecha-
nism is important for preventing reproduction of
DNA damage and to give the cell time for DNA repair.
This capacity of p53 may have the function of elimi-
nating those cells in which DNA repair has not been
successful. Cells that lack active p53 protein, because
of mutation or binding onto other cellular or viral
proteins, are not arrested in the Gl-phase and do not
undergo apoptosis.99 Such cells are consequently
genetically less stable and may develop malignant
cell clones.1 Circumstantial evidence exists to pos-
tulate that p53 induces survival factor dependence in
the involved cell.ml
The role of the p53 protein can be summarized as
follows:
DNA damage -+ p53 protein
--+ increases survival factor dependence
--+ arrest in G1 until repair is completed
--> apoptosis if repair fails
DNA damage --> p53 protein --
mitotic failure, cell death
-+ progress to malignancy
ced-3/ICE. Recently a cell suicide gene responsible
for programmed cell death in Caenorhabditis elegans
(ced-3) has been cloned.12 It was demonstrated that
the gene product is a protein, very similar to
interleukin-l-converting enzyme (ICE). ICE, a
cysteine protease, cleaves the inactive precursor of
IL-1 to generate an active cytokine. ICE causes
apoptosis in rat fibroblasts in which the ICE gene was
introduced and brought to expression,m3 In addition
it was found that bcl-2 could inhibit the cell death
brought on by over-expression of ICE gene. The
researchers concluded that members of the ced-3/
ICE gene family might function in apoptotic cell
death in vertebrates.
MTS1. MTS1 (multiple tumor suppressor 1) en-
codes for a previously identified inhibitor (p16) of
cyclin-dependent kinase 4 (cdk-4). This gene prod-
uct prevents the activation of c-myc by blocking an
enzyme in the pathway that allows messages from
the cell surface receptors to switch on c-myc. In 46%
of 290 different human cancers functional copies of
MTS1 are missing leaving c-myc unchecked and the
pathway to cell division open.TM
Apoptosis and Inflammation
Bacterial infections: The principal event that leads to
inflammatory disease is cell damage, which can be
induced by bacterial or viral toxins, chemical or
physical injury, anoxia, starvation, or allergic auto-
immune attack. Massive cell damage and necrosis
result in leakage of cell contents into the adjacent
tissues. Dissipation of enzymes and mediators of
inflammation, released from the necrotic cells, results
in expression of adhesive molecules on endothelial
cells and on the neutrophils. Receptors on
granulocytes and monocytes (and lymphocytes),
such as Mac-l, LFA-1 and P150.95 (VLA-4), with high
affinity for the adhesion peptides (integrins), interact
with their counterparts on the endothelium (ELAM-
1, ICAM-1, ICAM-2 and VCAM-1). This mechanism
promotes the capillary transmigration of these cells to
the injured tissue. The expression of adhesins is
upregulated by IL-1, TNF and by exposure to
chemotaxins such as C’5a, IL-8. The accumulation of
neutrophils and release of enzymes and oxygen
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radicals from the attracted granulocytes underlie the
inflammatory reaction.
An inflammatory reaction is not always a salutory
response to injurious events. Neutrophil
granulocytes have been implicated in the
pathogenesis of a wide variety of diseases.15 They
contain a large number of agents with the capacity to
injure tissue and to degrade matrix proteins into
chemotactic fragments.16 Persistent accumulation of
inflammatory cells is associated with destruction of
tissue matrix or deposition of scar tissue and can lead
to the loss of organ function. Examples of such
catastrophic organ damage are given by lung emphy-
sema, respiratory distress syndrome, fibrosing
alveolitis, pneumoconiosis, liver cirrhosis, forms of
glomerulonephritis, and rheumatoid arthritis.
For inflammatory tissues to return to normal, all the
events involved in the evolution of inflammation
must be reversed. These must include removal of the
inciting stimulus, cessation of neutrophil accumula-
tion, cessation of further release of histotoxic and
pro-inflammatory mediators, return of microvascular
permeability to normal and cessation of monocyte
emigration from blood vessels. The tissue monocytes
must transmutate into macrophages, which remove
extravasated fluid, proteins, bacterial and cellular
debris and accumulated neutrophils. Cessation of
neutrophil and monocyte emigration may occur after
dissipation of chemotactic factors from the inflamed
tissue, but the mechanism for the loss of chemotaxins
has not yet been identified.
Recent reviews dealing with the general aspects of
inflammation have been given by Saukkonen et
al., 17 Haslett,
18 Dinarello and Wolff,19 and Bonta
and Ben-Efraim.11 The following paragraph is re-
stricted to the role of apoptosis in the clearance of
granulocytes from the ’battlefield’ of inflammation by
macrophages.
Granulocytes, where they have infiltrated, release
enzymes, oxygen radicals, cytokines and mediators
of inflammation, locally. All these products may trig-
ger potentially dangerous responses within the or-
ganism. This aspect of inflammation has led to much
research into enzyme inhibitors, oxygen radical scav-
engers and membrane stabilizers, but little attention
has been paid to factors controlling the accumulation
and the tissue load of granulocytes and their
histotoxic products.
Tissue kinetics of neutrophils depend upon the
half-life of the neutrophils, the amount of
neutrophils that enter the tissue per time unit, and
the speed by which they are removed. Lee et al.TM
have shown that bacterial products such as
lipopolysaccharide, the chemotactic peptides C5a
and GM-CSF, all exert an inhibitory effect on the rate
of neutrophil apoptosis. Concentrations of these
mediators are likely to be high in acutely infected
tissues, but vary considerably during resolution and
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in chronic inflammation. Neutrophil apoptosis may
represent an important event in the control of inflam-
mation, eliminating the neutrophil for disposal and
for its capacity to generate and release histotoxic
products.47 The efficient removal of neutrophils from
inflamed sites, once their biological purpose (killing
of invading pathogens, breakdown of cell debris) is
completed, is a highly desirable and effective mecha-
nism on the road to reconstitution of the normal
situation. Neutrophils can undergo apoptosis and the
associated changes of the cell surface aid their
phagocytosis by macrophages. 46 It has been assumed
that granulocytes disintegrate to apoptotic bodies
before their fragments are removed by local
macrophages.
112 Removal of neutrophils from the
inflammatory site, without release of granule con-
tents, is of paramount importance for cessation of
inflammation. Neutrophil apoptosis is accelerated by
TNF.13 This process operates wherever a need
exists to curtail a suppurative exudation, be it the
resolution of an exsudative infection or the
obturation of an abscess cavity.
The rate of apoptosis of human eosinophils, al-
ready slower than that reported for neutrophils, is
delayed in vitro by the eosinophil differentiation
factor IL-5. 24’58’59
The processes involved in the control of monocyte
recruitment have not yet been elucidated, although
very likely they are governed by similar principles as
described under neutrophil emigration.
Macrophages play an important role in reconstitution
of normal haemodynamics and recovery of tissue
integrity after inflammation. Monocytes are mobi-
lized to the site of inflammation by C’5a, MLP, MCP-
1 and TGF[. Their elimination from the inflammatory
site presumably takes place mostly by apoptosis,
which is promoted by IL-4 (<---TH-2 cells) and inhib-
ited by GM-CSF/M-CSF, IL-3, IFN(<--TH-1 cells), IL-
l and TNFO.TM
Viral infections: Viruses have developed strategies to
inhibit apoptosis following virus infection, which
serves to prolong the life of their target cells and
promote virus replication. Epstein-Barr virus induces
the expression of bcl-2 related genes in the infected
cells and encodes for a bcl-2 homologue,15 including
EIB in adenovirus, LMW5-HL in African swine fever
virus, BHRF1 in Epstein-Barr virus infection. 115-118
Presumably, adenovirus, human papilloma viruses
and SV40 modulate apoptosis also by interaction of
viral proteins with cellular P53.
It has recently been suggested that both qualitative
and quantitative defects in CD4+ T cells in patients
with HIV infection may be the result of activation-
induced cell death by apoptosis.19-22 Since apoptosis
can be induced in mature murine CD4+ T cells after
cross-linking of CD4 molecules, uncoupled from TCR
triggering, there has been speculation that cross-Apoptosis and inflammation
linking of the CD4 molecule by HIV gp120 or by
gp120/anti-gp120 immune complexes prepares the
cell for apoptosis that occurs when MHC class II
molecule presents an antigen to the TCR.77,121,122
Thus, the mere activation of a prepared cell by a
specific antigen or superantigen could lead to the
death of the cell, without direct infection by HIV.
Apoptosis of CD8+ cells has been obscured in vitro
even in the absence of an antigenic stimulus. 123,124
Concluding remarks
Cell death plays an important role in
immunogenesis, during inflammation and in the
resolution of inflammatory reactions. The mecha-
nisms and mediators involved have not yet been fully
elucidated, but there is evidence that surrounding
cells adjacent to inflammation kill themselves by
apoptosis, increasing the damage caused by inflam-
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matory reactions. In Fig. 1 the various biological
processes that mediate and modulate {he inflamma-
tory reaction and the role of apoptosis are depicted
schematically. The facts known so far have been put
together in this review in order to draw attention to
apoptosis and to stimulate further research on its role
in inflammatory diseases.
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